News
MarkHerz Inc., a biotechnology company specializing in AAV-based gene therapies targeting cardiovascular and metabolic diseases, announced that it has signed a Memorandum of Understanding (MOU) on May ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback